within Pharmacolibrary.Drugs.ATC.S;

model S01AA23
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0013333333333333333,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00015,
    k12             = 0.065,
    k21             = 0.065
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01AA23</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Netilmicin is a semisynthetic aminoglycoside antibiotic derived from sisomicin. It is used to treat serious bacterial infections, particularly those caused by Gram-negative bacteria, and is typically reserved for use when other aminoglycosides may not be effective due to resistance. It is primarily administered parenterally due to poor absorption orally. While it has been clinically used in the past, current use is limited due to concerns about nephrotoxicity and ototoxicity, and safer alternatives being available.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adults with normal renal function following intravenous administration.</p><h4>References</h4><ol><li><p>Welling, PG, Baumueller, A, Lau, CC, &amp; Madsen, PO (1977). Netilmicin pharmacokinetics after single intravenous doses to elderly male patients. <i>Antimicrobial agents and chemotherapy</i> 12(3) 328–334. DOI:<a href=&quot;https://doi.org/10.1128/AAC.12.3.328&quot;>10.1128/AAC.12.3.328</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/907325/&quot;>https://pubmed.ncbi.nlm.nih.gov/907325</a></p></li><li><p>Michalsen, H, &amp; Bergan, T (1981). Pharmacokinetics of netilmicin in children with and without cystic fibrosis. <i>Antimicrobial agents and chemotherapy</i> 19(6) 1029–1031. DOI:<a href=&quot;https://doi.org/10.1128/AAC.19.6.1029&quot;>10.1128/AAC.19.6.1029</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7271272/&quot;>https://pubmed.ncbi.nlm.nih.gov/7271272</a></p></li><li><p>Jauregizar, N, Wald, JA, Astobieta, A, Rodriguez Sasiain, JM, Lukas, JC, &amp; Calvo, R (2003). Population pharmacokinetics of netilmicin in short-term prophylactic treatment. <i>British journal of clinical pharmacology</i> 55(6) 552–559. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2125.2003.01783.x&quot;>10.1046/j.1365-2125.2003.01783.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12814449/&quot;>https://pubmed.ncbi.nlm.nih.gov/12814449</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01AA23;
